ITI Pharma and Healthcare Fund - Regular Plan - Growth Option
💡 Why Pick This Fund? Quantitative Strengths & Watch-outs
- Outperformed category benchmark in 100% of historical 3-year rolling periods.
- Strong capital defense: downside capture of 72% limits losses during market corrections.
- Generated +7.9% annualized alpha (excess return) over its benchmark.
- Equities carry market risk; returns fluctuate and recommended investment horizon is 5+ years.
Key Statistics vs Category Median
Trailing Returns Comparison
| Period | Fund Return | Category Median | Difference |
|---|---|---|---|
| 1 Month | +8.23% | +6.32% | +1.91% |
| 3 Months | +2.31% | -0.20% | +2.51% |
| 6 Months | +11.81% | +5.98% | +5.83% |
| 1 Year | +15.35% | +3.90% | +11.45% |
| 3 Years CAGR | +18.46% | +13.23% | +5.23% |
| 5 Years CAGR | +13.33% | +10.72% | +2.61% |
| Since Inception | +13.33% | - | - |
📈 Monthly SIP vs Bank Fixed Deposit (FD) Replay
See how a regular monthly SIP in ITI Pharma and Healthcare Fund compares against a standard 7.0% p.a. Bank Fixed Deposit.
Calendar Year Returns
| Year | Fund | Category Median | Gap |
|---|---|---|---|
| 2026 | +19.15% | +4.03% | +15.12% |
| 2025 | -9.96% | +1.43% | -11.39% |
| 2024 | +41.25% | +20.41% | +20.84% |
| 2023 | +31.61% | +30.70% | +0.91% |
| 2022 | -8.68% | +1.66% | -10.34% |
Daily Rolling Returns Summary
| Rolling Window | Minimum | Average | Median | Maximum | % Positive | % Beating Proxy |
|---|---|---|---|---|---|---|
| 1-Year Rolling | -11.02% | +16.69% | +12.97% | +58.89% | 73.8% | 64.0% |
| 3-Year Rolling | +15.04% | +19.40% | +19.11% | +25.03% | 100.0% | 99.6% |
Risk Profile & Deepest Drawdowns
Deepest Market Corrections (Depth >= 10%)
| Peak Date | Trough Date | Fall Depth | Months to Bottom | Recovery Period |
|---|---|---|---|---|
| 2022-01-13 | 2022-06-17 | -18.5% | 5 months | 13 months |
| 2025-01-02 | 2026-01-29 | -17.6% | 13 months | 5 months |
| 2026-09-23 | 2026-10-23 | -10.1% | 1 months | 1 months |
Portfolio & Asset Allocation
Statutory Asset Allocation Mandate (SEBI / SID)
| Instrument Category | Permitted Allocation Range |
|---|---|
| Equity, Units issued by REITs & Equity related instruments of companies engaged in pharma and healthcare 80%-100%, Equity, Units issued by REITs and Equity related securities of other Companies 0%-20%, Listed Preference Shares 0%-10%, Debt and Money Market Instruments 0%-20%, Units issued by InvITs 0%-10% | Per Scheme Mandate |
Investment Objective & Strategy
The investment objective of the scheme is to seek to generate long term capital appreciation through investing in equity and equity related securities of companies engaged in Pharma and Healthcare. However, there can be no assurance that the investment objective of the scheme would be achieved.
ℹ️ Detailed monthly stock-level holdings for this scheme are updated periodically from asset management company statutory disclosures.
Fund Size Position
Currently managing Rs 283 cr (AMFI Daily Fund AUM as of 2026-11-11). Positioned as small relative to Sectoral / Thematic schemes.
Fund Management
Cost & Capital Gains Taxation
From April 2026 the total expense ratio includes brokerage, transaction costs and statutory levies on top of the base fee.
Equity-oriented schemes: 20% short-term capital gains tax if sold within 12 months; 12.5% long-term capital gains tax on gains exceeding ₹1.25 lakh per financial year when held for more than 12 months.
Closest Sectoral / Thematic Peers by Rank
| Scheme | Score | 3Y Return | Expense | Downside | Fund Size | Compare |
|---|---|---|---|---|---|---|
| Aditya Birla Sun Life Special Opportunities Fund | 7.1 | +18.81% | 2.26% | 78.6% | Rs 1,475 cr | Compare → |
| Aditya Birla Sun Life Manufacturing Equity Fund | 6.0 | +19.80% | 2.32% | 100.0% | Rs 1,407 cr | Compare → |
| Kotak Pioneer Fund | 7.3 | +18.33% | 1.90% | 77.2% | Rs 4,405 cr | Compare → |
| Tata India Pharma & Healthcare Fund | 6.2 | +17.37% | 2.40% | 65.7% | Rs 1,589 cr | Compare → |
| LIC MF Healthcare Fund | 7.1 | +20.28% | 2.72% | 59.8% | Rs 101 cr | Compare → |
Frequently Asked Questions about ITI Pharma and Healthcare Fund
What is the expense ratio of ITI Pharma and Healthcare Fund?
ITI Pharma and Healthcare Fund has a total expense ratio (TER) of 2.57% with a base expense ratio of 2.1%, compared to the Sectoral / Thematic category median of 2.52%.
Who manages ITI Pharma and Healthcare Fund?
ITI Pharma and Healthcare Fund is managed by Animesh Singh (tenure: 0.5 years since 2026-05-08).
What are the historical returns of ITI Pharma and Healthcare Fund?
ITI Pharma and Healthcare Fund delivered a 3-year CAGR of 18.46% and a 5-year CAGR of 13.33%. Its 1-year return stands at +15.35%.
How large is ITI Pharma and Healthcare Fund?
ITI Pharma and Healthcare Fund manages assets of Rs 283 cr, placing it in the 'small' size band relative to Sectoral / Thematic peers.
How is ITI Pharma and Healthcare Fund scored on MFIQ?
ITI Pharma and Healthcare Fund holds an MFIQ Score of 6.6/10 (Average), based on a category percentile composite across returns, risk, consistency, and cost.
How risky is ITI Pharma and Healthcare Fund?
ITI Pharma and Healthcare Fund has an official SEBI riskometer rating of Very High. Over the analyzed period, its annualized standard deviation is 14.42% with a maximum historical drawdown of -18.53%.